Dapagliflozin induces apoptosis by downregulating cFILP<sub>L</sub> and increasing cFILP<sub>S</sub> instability in Caki-1 cells.
Dapagliflozin透過降低cFILP<sub>L</sub>並增加Caki-1細胞中cFILP<sub>S</sub>的不穩定性誘導細胞凋亡。
Oncol Lett 2022-10-25
SGLT-2 as a potential target in pancreatic cancer: the preliminary clue from The Cancer Genome Atlas data.
SGLT-2作為胰臟癌潛在治療靶點:來自癌症基因組圖譜數據的初步線索。
J Gastrointest Oncol 2022-11-19
[Preliminary Investigation of the Molecular Mechanism of Empagliflozin Suppressing Gastric Cancer Through Mammalian Target of Rapamycin].
Empagliflozin 抑制胃癌通過哺乳動物雷帕黴素靶向的分子機制初步研究
Sichuan Da Xue Xue Bao Yi Xue Ban 2024-01-03
Exploring the therapeutic potential of SGLT2 inhibitors in cancer treatment: integrating in silico and in vitro investigations.
探索SGLT2抑制劑在癌症治療中的治療潛力:整合體外和體內研究。
Naunyn Schmiedebergs Arch Pharmacol 2024-02-28
SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells.
SGLT2抑制劑促進結腸癌細胞的粒線體功能障礙和內質網吞噬。
Cell Mol Biol Lett 2024-05-29
Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohort study.
第二型糖尿病患者新發胃癌及胃疾病的鈉葡萄糖共同轉運蛋白2抑制劑的比較效果:一項基於人口的cohort研究。
Gastric Cancer 2024-06-10